Michael Martin Breen
Exec Chairman and Interim CEO at GT Biopharma Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: GT Biopharma Inc., 3 years.
GT Biopharma Inc.
Director · CEO and Director
Prairie Operating Co.
Director
Chief executive roles
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 11, 2023 | GT Biopharma Inc. | Grant or award | +200,000 | $0.29 | $58,000 |
| May 3, 2023 | Prairie Operating Co. | Open-market purchase | +916,112 | $0.11 | $100,772 |
| May 3, 2023 | Prairie Operating Co. | Grant or award | +218,571 | $0.18 | $39,343 |
| Apr 11, 2023 | GT Biopharma Inc. | Open-market purchase | +50,000 | $0.50 | $25,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.